Eysuvis™ (loteprednol etabonate ophthalmic suspension 0.25%; Kala Pharmaceuticals) is now available for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease.
Loteprednol etabonate, a corticosteroid, targets the immune responses that lead to acute dry eye disease flares. Eysuvis utilizes the Company’s proprietary technology to enhance penetration of loteprednol etabonate into the target tissue of the ocular surface.
The approval was based on data from 4 clinical trials, including three phase 3 trials (STRIDE 1, STRIDE 2 and STRIDE 3) and one phase 2 trial, assessing the efficacy and safety of Eysuvis in approximately 2900 patients with dry eye disease. Results from these trials showed that treatment with Eysuvis was associated with significant improvements in both the signs and symptoms of dry eye disease.
“We are looking forward to bringing this important new therapy to the millions of dry eye disease patients who suffer from episodic flares but did not have an FDA-approved rapid-acting, prescription treatment option prior to Eysuvis,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals.
Eysuvis is supplied as 2.5mg/mL of loteprednol etabonate in an 8.3mL suspension. The Company is offering a copay savings card to assist eligible patients.
For more information visit eysuvis.com.
Kala Pharmaceuticals announces availability of Eysuvis™ for the treatment of dry eye disease and provides update on development pipeline. [press release]. Watertown, MA: Kala Pharmaceuticals; January 7, 2021.